Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Merck and Kelun-Biotech Adjust their ADC Partnership

publication date: Aug 20, 2024

Merck (MSD) has altered its mammoth ADC partnership with Sichuan’s Kelun-Biotech by adding one candidate and dropping another. In 2022, Merck made major news by entering three partnerships with Kelun worth a maximum of $12.7 billion. Now, Merck plans to acquire a global license to SKB571, a bispecific ADC aimed at solid tumor cancers, paying $37.5 million upfront. At the same time, it returned rights to SKB315, a CLDN18.2 ADC. The agreement between the two companies is well underway: Kelun received $90 million in milestone payments from Merck in the first half of 2024. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here